Overview

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC). The hypothesis is that IO102 will improve the objective response rate (ORR) in patients with metastatic NSCLC.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

IO Biotech

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Carboplatin
Pembrolizumab
Pemetrexed